- Home
- CASI vs IGC Comparison
CASI vs IGC Comparison
Compare CASI & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASI
- IGC
- Stock Information
- Founded
- CASI 1991
- IGC 2005
- Country
- CASI China
- IGC United States
- Employees
- CASI N/A
- IGC N/A
- Industry
- CASI Biotechnology: Pharmaceutical Preparations
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- CASI Health Care
- IGC Health Care
- Exchange
- CASI Nasdaq
- IGC Nasdaq
- Market Cap
- CASI 35.8M
- IGC 39.8M
- IPO Year
- CASI 1996
- IGC N/A
- Fundamental
- Price
- CASI $1.84
- IGC $0.41
- Analyst Decision
- CASI Strong Buy
- IGC Strong Buy
- Analyst Count
- CASI 1
- IGC 2
- Target Price
- CASI $4.00
- IGC $4.00
- AVG Volume (30 Days)
- CASI 305.0K
- IGC 667.7K
- Earning Date
- CASI 11-13-2025
- IGC 11-11-2025
- Dividend Yield
- CASI N/A
- IGC N/A
- EPS Growth
- CASI N/A
- IGC N/A
- EPS
- CASI N/A
- IGC N/A
- Revenue
- CASI $31,564,000.00
- IGC $1,327,000.00
- Revenue This Year
- CASI N/A
- IGC $15.26
- Revenue Next Year
- CASI N/A
- IGC $3.41
- P/E Ratio
- CASI N/A
- IGC N/A
- Revenue Growth
- CASI 36.64
- IGC 24.95
- 52 Week Low
- CASI $1.09
- IGC $0.25
- 52 Week High
- CASI $7.50
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- CASI 51.04
- IGC 50.95
- Support Level
- CASI $1.77
- IGC $0.39
- Resistance Level
- CASI $2.08
- IGC $0.43
- Average True Range (ATR)
- CASI 0.20
- IGC 0.02
- MACD
- CASI 0.02
- IGC -0.00
- Stochastic Oscillator
- CASI 71.84
- IGC 37.17
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.